When Galena Biopharma, Inc. (NASDAQ: GALE) stock gained nearly 60% in 2 weeks it certainly raised some eyebrows. So here at TKO we took a closer look at this small cap company for some answers.
A quick look at GALE financials certainly isn’t a reason to jump on the Galena Biopharma train if you’re looking for operational profits. With a quarterly cash burn of around $10 million and $52 million in cash, another round of financing is around the corner probably in middle to late 2016.
However, a peek at the GALE product pipeline is promising. Galena Biopharma focuses on developing and commercializing oncology therapeutics which are largely unmet in the cancer care market. This Investopedia article covers their products including Abstral, Zuplenz and their flagship breast cancer product NeuVax. The article also points to a glowing analyst report from Maxim Group as the reason for the recent GALE stock mini-meteoric rise. We surmise that the Maxim Group target price of $7.00 per share attracted the attention of day traders pushing volume well above averages.
Galena Biopharma, Inc. (GALE) is certainly a small cap pharma stock to watch. The success of Neuvax would make $1.50 a share a very shrewd investment, but commercialization is certainly years down the road giving investors plenty of opportunities to jump on board. GALE is currently selling at $1.87 per share above a 52-week low of $1.27 (May 8, 2015) and high hitting $3.36 a share back in July, 2014.